"Pharmaceutical Speed Reader" Baiji financing 2.08 billion U.S. dollars Enhua children's new products proposed priority review.

July 14, 2020 / Medical Information List: Baiji Shenzhou raised a record $2.08 billion; the development of a potential cure for HIV, Mersadon, reached a $300 million cooperation; Junshi Bio and REVITOPE signed a research and development cooperation and license agreement; Fosun's new crown vaccine clinical application was accepted; and the amycini-thermal lipid regime agent Phase III clinical lysage ..Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Briefing National Health and Health Commission: Epidemic prevention and control under the normalization of further improve the pre-hospital medical emergency response capacity 13, the National Health and Health Commission issued "the National Health and Health Commission Office on the new crown pneumonia epidemic prevention and control under the normalization of the notice to further improve the pre-hospital medical first aid response capacity", the new crown pneumonia epidemic prevention and control of the normal pre-hospital medical first aid work to put forward specific requirements(National Health and Health Commission) Medtronic lost supplies winning the bid results announced on the 13th, Qujing City, Yunnan Province, medical supplies joint procurement office announced the public announcement, has completed the first batch of public medical institutions in 2020 high-value medical supplies alliance volume centralized procurement of the first batch of on-site negotiationsinclude coronary dilating balloons, coronary guide guide tubes, coronary guide guides, double-cavity pacemakers, and pace electrode wiresthe list of the proposed finalists announced this time only includes 10 armed enterprises, Medtronic, Lepu, Shandong Jiwei and other armed enterprises are not on the list(Qujing City, Yunnan Province, medical supplies joint procurement office) Part 2 production and observation OfiJi Shenzhou financing 2.08 billion U.Sdollars record Baiji Shenzhou announced that it will issue 145,838,979 new shares to major shareholders, accounting for about 12.5% of the total number of shares issued after the issue, the purchase price of $14.2308 per share, total issuance revenue of about $2.08 billion, net of net income after the issuance of $2.07 billion in the world's largest equity financing(Baiji Shenzhou Announcement) to develop a potential cure for HIV, Mercadon reached a $300 million cooperation on July 13 local time, Mercadon and Boston-based Dewpoint Therapeutics jointly announced that the two sides have reached a partnership based on the latter's proprietary biomolecular cohesion drug discovery platform, the joint development of new mechanism therapy for HIV, in order to find a cure for this catastrophic diseaseunder the terms of the agreement, Mersadon will pay Dewpoint $305 million in advance sand and milestone paymentsdid not disclose the process of developing HIV therapy in connection with the partnership(Sina Pharmaceutical News) Junshi Bio and Oncology Pharmaceuticals company REVITOPE signed a research and development cooperation and license agreement Junshi Bio announced that the company and Revitope signed a research and development cooperation and license agreementunder the agreement, the two sides will use Revitope's dual antigen-oriented T-cell embedded activation technology platform and the company's antibody technology platform to develop a new generation of T-cell inset activation tumor immunotherapy(Sina Pharmaceutical News) PolarIs announced a $32 million Round A financing to actively promote innovative ophthalmology therapy Polaroids announced an agreement on $32 million in round A financingthis round of financing by Morninggoing Ventures, the original incubation investor sanfeng life technology, Dingfeng Shengke Capital continued to add investment, all three institutions are committed to long-term to build the global life and health of outstanding enterprises(Pharma Rubik's Cube) Part 3 Pharmaceutical News Roche Tecentriq First Line Treatment of Advanced Ovarian Cancer Phase III Study did not reach the main end point of PFS on the 13th, Roche announced that Tecentriq (Atlizumab) joint Avastin (Bevalju monotag), symitol and capipanie first line treatment patients with advanced ovarian cancer patients Phase III IMgyn50 study failed to reach the main end point, compared to the control group did not significantly improve the survival progress of the phase 1the security data of the study is consistent with previously known security results(Pharma Rubik's Cube) Roche Hemlibra is safe and effective in patients with factor VIII inhibitors in the body! Roche recently released the second interim results of the Phase III STASEY study, which enhanced Hemliba's safety in the Phase III HAVEN clinical project in the STASEY study, Hemlibra was effective in adult sepsis A patients with type A patients with factor VIII inhibitors in the body, and no new safety signals were found, consistent with previous safety observations further analysis of the data showed that patients treated with Hemliba were able to perform some minor surgery without the use of additional preventive coagulation factors (Biovalley) Amycin pyrethronic regime agent Phase III Clinical Critical Celsion announced that its Amycin pyrethroias Isoactive regime agent ThermoDox PHASE III Clinical Independent Data Monitorrecommend recommended the termination of the trial, called OPTIMA second mid-term analysis showed that the experiment had exceeded the previously set invalid threshold, but because of some uncertainty in the p-value, the DMC left the decision to the CLSN the trial recruited 554 patients with primary liver cancer of 3-7 cm, comparing the effects of ThermoDox with RFA and the use of RFA alone on OS, with PFS as a secondary endpoint (U.S Herbal Medicine Source) Pfizer/BioNTech New Crown Vaccine was FDA Fast Track Qualification Pfizer and BioNTech jointly announced that bnT162b1 and BNT162b2 are two candidate vaccines that have been granted fast-track status by the FDA the two vaccines, evaluated in Phase 1/2 clinical trials currently under study in the United States and Germany, are the two fastest-growing candidates in the two companies' new-crown vaccine development programs (Pharmaceutical Mingkang) Wantai Bionew Crown Testing Products obtained the U.S FDA Emergency Use Authorization Wantai Bio announced that the company's new coronavirus antibody rapid detection kit (colloidal gold method) in the United States on July 10, 2020 u.S time to obtain the U.S FDA issued emergency use authorization (Sina Pharmaceutical News) U.S FDA approves Ipson Dysport: Treatment of 2-year-old children due to cerebral palsy upper limb spasms Epson Inc.'s Epson Biopharmaceutical Company recently announced that the U.S FDA has approved the expansion of Dysport (Chinese name: Lishuato, abotulintoxinA, type A botox toxin) injection, the treatment of the upper limbs and lower limb spasms caused by the treatment of cerebral palsy (Biovalley) FDA awarded Assembly's second-generation core inhibitor ABI-H2158 fast-track eligibility Assembly Biosciences recently announced that the U.S FDA has awarded ABI-H2158 fast track eligibility, the second-generation core protein inhibitor of Assembly, which is currently being evaluated in a global Phase II clinical trial (BioValley) Bristol-Myers Squibb K.K., japan subsidiary of Bristol-Myers Squibb K.K., announced that it had filed a listing application for liso-cel in Japan under the category of Regenerative Medicine The indications are the second country to submit a listing application for the treatment of patients with recurrent/refractive large B-cell lymphoma for the treatment of at least two previous lysic systems, and liso-cel filed a listing application with the U.S FDA late last year and is currently under review (Medical Valley) Weiwei anti-insomnia drug lemborexant submitted a new drug application to Hong Kong, China, 13, The Ishigs announced that the Hong Kong Department of Health has accepted the application for a new drug, approved its in-house development of the appetite receptor antagonist Dayvigo for the treatment of adult insomnia, the disease is manifested in sleep and/or maintenance of sleep disorders this is Dayvigo's first listing in Asia outside Japan (Drug MingKangd) Hengrui "ground quarpsss sodium eye drops" first copy reported the listing of Hengrui 4 class generic drugs "ground phosphorescous sodium eye drops" listing application by CDE, is the first domestic generic drug production of the variety (CDE) Fosun New Crown Virus mRNA Vaccine Was Registered review of clinical trials accepted Fosun Pharma's announcement that the company's controlling subsidiary Fosun Pharmaceutical Industry recently received a "receiving notice" of its licensed new coronavirus mRNA vaccine (BNT162b1) for the prevention of new coronaviruses by the State Drug Administration clinical trial registration review acceptance (Sina Pharmaceutical News) Fosun Pharma Bcl-2 Selective Inhibitor FCN-338 approved clinical CDE official website shows that Fosun Pharma Class 1 new drug FCN-338 tablets have been clinically impliedly approved for the treatment of malignant tumors of the blood system (CDE) Fuhong Hanxuan "Litoxi monoidatis" 2 new adaptations approved by Star Pharma issued an announcement, its holding subsidiary Shanghai Fuhong Hanxuan "Litoxi monitamcine injection" 2 indications approved by the State Drug Administration 2 new indications are: (1) single-drug maintenance therapy in patients with primary treatment of osfolic lesmal mlymoma after full or partial remission after hyperlodone combined chemotherapy; (CDE) won the first review! Qilu 35 products review leader NMPA official website announced the latest batch of drug approval certificate information, Qilu Pharmaceutical's single nitric acid hetero-sander slow release tablets through consistent evaluation, become the first evaluation of the product enterprise -meter net statistics, so far, Qilu Pharmaceuticals has evaluated 35 products (60 approvals) to become the leader of consistency evaluation (minnet.com) Enhua children's new products to be priority review Exclusive declaration impact the domestic first imitation CDE official website announced the latest proposed priority review varieties, Enhua Pharmaceuticals' hydrochloric acid Midazolam syrup (acceptance number CYHS2000375) to be prioritized for the review of the reasons for "in line with the physiological characteristics of children's new quality, dosage form, specifications", the current domestic market has not been approved for listing of the product, no other drug listed (Minnet.com) Shenwei 2020 the first listing declaration came the latest cDE data show that Shandong Kongfu Pharmaceutical and Shenwei Pharmaceutical Group jointly declared the Malay acid Afatini tablets 4 types of imitation listing application was accepted only Hausen Pharmaceuticals in China in June 2020 was approved for the first imitation, earlier has been Collum, Stone Pharmaceuticals, Yangzijiang and other six pharmaceutical companies to declare and review (mnet)